Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Immunotherapy × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 68 Hodgkin Disease 49 Lymphoma 19 Sarcoma 13 Neoplasm Metastasis 10 Leiomyosarcoma 8 Skin Neoplasms 6 Neoplasms 6 Uveal Melanoma 5 Sarcoma, Synovial 3 Recurrence 3 Solitary Fibrous Tumors 2 Sarcoma, Alveolar Soft Part 2 Neuroblastoma 2 Thyroid Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Melanoma Neoplasms 1 Lung Neoplasms 1 Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1 Liposarcoma 1

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Immunotherapy, Adoptive 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04225390 2026-02-10

PROMIT

University of Erlangen-Nürnberg Medical School

Phase 2 Completed

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡